Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry

Efficacy and Safety of Vedolizumab for Induction of Remission in Inflammatory Bowel Disease—the Israeli Real-World Experience

(2017) Uri Kopylov et al.   INFLAMMATORY BOWEL DISEASES

Vedolizumab as Induction and Maintenance Therapy for Crohnʼs Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy

(2017) Bruce E. Sands et al.   INFLAMMATORY BOWEL DISEASES

Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG)

(2017) Carl Eriksson et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

Vedolizumab induction therapy for inflammatory bowel disease in clinical practice - a nationwide consecutive German cohort study

(2016) D. C. Baumgart et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study

(2016) A. Stallmach et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The Real-World Effectiveness and Safety of Vedolizumab for Moderate–Severe Crohn’s Disease: Results From the US VICTORY Consortium

(2016) Parambir S Dulai et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Effectiveness and Safety of Vedolizumab Induction Therapy for Patients With Inflammatory Bowel Disease

(2016) Aurelien Amiot et al.   Clinical Gastroenterology and Hepatology

The safety of vedolizumab for ulcerative colitis and Crohn's disease

(2016) Jean-Frédéric Colombel et al.   GUT

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target

(2015) L Peyrin-Biroulet et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Vedolizumab for Induction and Maintenance of Remission in Ulcerative Colitis

(2015) Mahmoud H. Mosli et al.   INFLAMMATORY BOWEL DISEASES

Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients

(2015) Edward Shelton et al.   INFLAMMATORY BOWEL DISEASES

Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed

(2014) Bruce E. Sands et al.   GASTROENTEROLOGY

Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis

(2013) Remo Panaccione et al.   GASTROENTEROLOGY

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

(2013) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

(2013) William J. Sandborn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-term durability of response to adalimumab in Crohnʼs disease

(2011) M. Chaparro et al.   INFLAMMATORY BOWEL DISEASES

Long-term Durability of Infliximab Treatment in Crohnʼs Disease and Efficacy of Dose “Escalation” in Patients Losing Response

(2011) María Chaparro et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Intensification of infliximab therapy in Crohn's disease: Efficacy and safety

(2011) M.Chaparro et al.   Journal of Crohns & Colitis

Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease

(2010) Jean Frédéric Colombel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review

(2009) Javier P Gisbert et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti- 4 7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases

(2009) D. Soler et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Use of the noninvasive components of the mayo score to assess clinical response in Ulcerative Colitis

(2008) James D. Lewis et al.   INFLAMMATORY BOWEL DISEASES